Pfizer Announces FDA Priority Review; EMA Acceptance of Regulatory Submission for Abrocitinib in Patients Over 12 Years of Age with Moderate to Severe Atopic Dermatitis
Pfizer announced the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s […]